CYRX vs IART

For growth investors, Integra LifeSciences Holdings Corporation (IART) is the stronger pick with 1.

5% revenue growth year-over-year, versus -24. 5% for Cryoport, Inc. (CYRX). Cryoport, Inc. (CYRX) offers the better valuation at 9. 1x trailing P/E, making it the more compelling value choice. Analysts rate Cryoport, Inc. (CYRX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cryoport, Inc.

(CYRX) delivered a total return of -79. 8%, compared to -81. 7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: CYRX returned +557. 7% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cryoport, Inc.

(CYRX) is the lower-risk stock at 1. 84β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 27% more volatile than CYRX relative to the S&P 500. On balance sheet safety, Cryoport, Inc. (CYRX) carries a lower debt/equity ratio of 46% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Integra LifeSciences Holdings Corporation (IART) is pulling ahead at 1.

5% versus -24. 5% for Cryoport, Inc. (CYRX). On earnings-per-share growth, the picture is similar: Cryoport, Inc. grew EPS 163. 3% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, IART leads at 1. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cryoport, Inc.

(CYRX) is the more profitable company, earning 39. 9% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 39. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IART leads at 4. 2% versus -20. 9% for CYRX. At the gross margin level — before operating expenses — IART leads at 51. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CYRX: -2.

0% to $12. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cryoport, Inc.

(CYRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+557. 7% 10Y return). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYRX: +557. 7%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CYRX (Industrials) and IART (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CYRX is a small-cap deep-value stock; IART is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.